Lista de obras -

A concise panel of biomarkers identifies neurocognitive functioning changes in HIV-infected individuals

artículo científico publicado en 2013

Abdominal obesity contributes to neurocognitive impairment in HIV-infected patients with increased inflammation and immune activation

artículo científico publicado en 2015

Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people

artículo científico publicado en 2014

Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline

artículo científico publicado en 2014

Brain morphometric correlates of metabolic variables in HIV: the CHARTER study

artículo científico publicado en 2014

CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy ⬇️

artículo científico publicado el 10 de septiembre de 2011

CSF biomarkers of monocyte activation and chemotaxis correlate with magnetic resonance spectroscopy metabolites during chronic HIV disease

artículo científico publicado en 2015

Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER Cohort

artículo científico publicado en 2013

Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration

artículo científico publicado en 2012

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV ⬇️

artículo científico publicado el 23 de noviembre de 2010

Etravirine in CSF is highly protein bound

artículo científico publicado en 2013

HIV Distal Neuropathic Pain Is Associated with Smaller Ventral Posterior Cingulate Cortex

artículo científico publicado en 2016

HIV-associated distal neuropathic pain is associated with smaller total cerebral cortical gray matter

artículo científico publicado en 2014

HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study

artículo científico publicado en 2010

Health-related quality of life 'well-being' in HIV distal neuropathic pain is more strongly associated with depression severity than with pain intensity

artículo científico publicado en 2012

Higher Anti-CMV IgG Concentrations are Associated with Worse Neurocognitive Performance During Suppressive Antiretroviral Therapy.

artículo científico publicado en 2018

Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy

artículo científico publicado en 2008

Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infection

artículo científico publicado en 2013

Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients

artículo científico publicado en 2015

Low atazanavir concentrations in cerebrospinal fluid

artículo científico publicado en 2009

Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration

artículo científico publicado en 2012

Mitochondrial DNA Haplogroups and Neurocognitive Impairment During HIV Infection

artículo científico publicado en 2015

Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER.

artículo científico publicado en 2012

Neurocognitive Impact of Substance Use in HIV Infection ⬇️

artículo científico publicado el 1 de octubre de 2011

Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study

artículo científico publicado en 2014

Neurocognitive functioning in acute or early HIV infection

artículo científico publicado en 2010

Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change

artículo científico publicado en 2011

Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study

artículo científico publicado en 2016

Predictors of new-onset distal neuropathic pain in HIV-infected individuals in the era of combination antiretroviral therapy

artículo científico publicado en 2015

Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy.

artículo científico publicado en 2016

Psychometric validation of the BDI-II among HIV-positive CHARTER study participants

artículo científico publicado en 2014

Reply to Haddow et al.

artículo científico publicado en 2015

Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder

artículo científico publicado en 2012

The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIV.

artículo científico publicado en 2014

The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk

artículo científico publicado en 2014

The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system

artículo científico publicado en 2007

Therapeutic amprenavir concentrations in cerebrospinal fluid

artículo científico publicado en 2012

Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1.

artículo científico publicado en 2010

Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system

artículo científico publicado en 2008

White matter damage, neuroinflammation, and neuronal integrity in HAND

artículo científico publicado en 2018

Lista de obras de

A concise panel of biomarkers identifies neurocognitive functioning changes in HIV-infected individuals

Abdominal obesity contributes to neurocognitive impairment in HIV-infected patients with increased inflammation and immune activation

Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people

Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline

Brain morphometric correlates of metabolic variables in HIV: the CHARTER study

CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy ⬇️

CSF biomarkers of monocyte activation and chemotaxis correlate with magnetic resonance spectroscopy metabolites during chronic HIV disease

Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER Cohort

Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV ⬇️

Etravirine in CSF is highly protein bound

HIV Distal Neuropathic Pain Is Associated with Smaller Ventral Posterior Cingulate Cortex

HIV-associated distal neuropathic pain is associated with smaller total cerebral cortical gray matter

HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study

Health-related quality of life 'well-being' in HIV distal neuropathic pain is more strongly associated with depression severity than with pain intensity

Higher Anti-CMV IgG Concentrations are Associated with Worse Neurocognitive Performance During Suppressive Antiretroviral Therapy.

Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy

Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infection

Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients

Low atazanavir concentrations in cerebrospinal fluid

Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration

Mitochondrial DNA Haplogroups and Neurocognitive Impairment During HIV Infection

Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER.

Neurocognitive Impact of Substance Use in HIV Infection ⬇️

Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study

Neurocognitive functioning in acute or early HIV infection

Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change

Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study

Predictors of new-onset distal neuropathic pain in HIV-infected individuals in the era of combination antiretroviral therapy

Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy.

Psychometric validation of the BDI-II among HIV-positive CHARTER study participants

Reply to Haddow et al.

Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder

The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIV.

The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk

The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system

Therapeutic amprenavir concentrations in cerebrospinal fluid

Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1.

Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system

White matter damage, neuroinflammation, and neuronal integrity in HAND